drugset / Trial / NCT00648401

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00648401

Phase 1 Completed 24 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following a single, oral 300 mg (1 x 300 mg) dose administration under fed conditions.

Timeline

Start
2006-01
Primary completion
2006-01
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Verapamil Other / unclassified 300 mg Oral
Comparator Verelan® PM Extended-Release Capsules, 300 mg Unknown 300 mg Oral

Indications

No indication recorded.